It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Mark Jacobson Biography and Net Worth

COO of Axsome Therapeutics

Mr. Jacobson has served as our Chief Operating Officer since March 2020 and has been a member of the Axsome team since April 2014.

Prior to joining Axsome, he was Director of Corporate Development at Stemline Therapeutics, Inc., where he played a critical role in advancing the company from a 3-person team in 2010 to the successful completion of an initial public offering and secondary public offering in 2013, which together raised approximately $100 million for the company. While at Stemline, Mr. Jacobson’s responsibilities spanned investor relations, public relations, corporate operations, and intellectual property. Mr. Jacobson began his career in healthcare communications at Publicis Healthcare Communications Group. Mr. Jacobson earned a Master of Arts in Biotechnology from Columbia University and a Bachelor of Science in Biology from Iowa State University.

What is Mark L. Jacobson's net worth?: The estimated net worth of Mark L. Jacobson is at least $547,071.80 as of August 9th, 2024. Mr. Jacobson owns 5,783 shares of Axsome Therapeutics stock worth more than $547,072 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Jacobson may own. Additionally, Mr. Jacobson receives a salary of $835,840.00 as COO at Axsome Therapeutics. Learn More about Mark L. Jacobson's net worth.
How old is Mark L. Jacobson?: Mr. Jacobson is currently 41 years old. There are 3 older executives and no younger executives at Axsome Therapeutics. The oldest executive at Axsome Therapeutics is Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & President, who is 56 years old. Learn More on Mark L. Jacobson's age.
What is Mark L. Jacobson's salary?: As the COO of Axsome Therapeutics, Inc., Mr. Jacobson earns $835,840.00 per year. The highest earning executive at Axsome Therapeutics is Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & President, who commands a salary of $1,400,000.00 per year. Learn More on Mark L. Jacobson's salary.
How do I contact Mark L. Jacobson?: The corporate mailing address for Mr. Jacobson and other Axsome Therapeutics executives is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. Axsome Therapeutics can also be reached via phone at (212) 332-3241. Learn More on Mark L. Jacobson's contact information.
Has Mark L. Jacobson been buying or selling shares of Axsome Therapeutics?: Mark L. Jacobson has not been actively trading shares of Axsome Therapeutics during the past quarter. Most recently, Mark L. Jacobson sold 47,739 shares of the business's stock in a transaction on Friday, August 9th. The shares were sold at an average price of $84.26, for a transaction totalling $4,022,488.14. Following the completion of the sale, the chief operating officer now directly owns 5,783 shares of the company's stock, valued at $487,275.58. Learn More on Mark L. Jacobson's trading history.
Who are Axsome Therapeutics' active insiders?: Axsome Therapeutics' insider roster includes Mark Coleman (Director), Mark Jacobson (COO), Roger Jeffs (Director), Nick Pizzie (CFO), and Mark Saad (Director). Learn More on Axsome Therapeutics' active insiders.
Are insiders buying or selling shares of Axsome Therapeutics?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 126,552 shares worth more than $10,005,148.57. The most recent insider tranaction occured on September, 11th when Director Mark E Saad sold 11,016 shares worth more than $1,005,870.96. Insiders at Axsome Therapeutics own 22.4% of the company. Learn More about insider trades at Axsome Therapeutics.
Information on this page was last updated on 9/11/2024.

Mark L. Jacobson Insider Trading History at Axsome Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/9/2024	Sell	47,739	$84.26	$4,022,488.14	5,783
5/29/2024	Sell	7,910	$74.31	$587,792.10	5,783
4/1/2024	Sell	24,662	$77.24	$1,904,892.88

Mark L. Jacobson Buying and Selling Activity at Axsome Therapeutics

Axsome Therapeutics Company Overview

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Today's Range

Now: $94.60

$94.24

$96.92

50 Day Range

MA: $90.69

$83.08

$99.49

2 Week Range

Now: $94.60

$58.61

$105.00

Volume

380,644 shs

Average Volume

620,052 shs

Market Capitalization

$4.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Tesla Execs are Freaking Out

From Angel Publishing | Ad

Click here to get the details.

Mark Jacobson Biography and Net Worth

What is Mark L. Jacobson's net worth?

How old is Mark L. Jacobson?

What is Mark L. Jacobson's salary?

How do I contact Mark L. Jacobson?

Has Mark L. Jacobson been buying or selling shares of Axsome Therapeutics?

Who are Axsome Therapeutics' active insiders?

Are insiders buying or selling shares of Axsome Therapeutics?